CBD vaporizer manufacturer Ispire Technology Inc. ISPR announced on Friday that it has halved the size of its planned initial public offering from six million shares to three million shares. The company stated that selling shareholders still plan to sell 1.75 million shares in the offering, with the price range maintained at $6 to $8 per share. If priced at the high end of the range, the company would raise $24 million, with a market valuation of $424 million. Tiger Brokers is the underwriter for the transaction. The funds raised will be used to establish manufacturing operations in Vietnam and the United States, as well as for research and development, marketing, and operating expenses. In the first half of 2022, the company's net loss was $2.95 million, with revenue of $58.8 million.
Reference list:
Ispire Technology, a manufacturer of vaping products, has reduced its planned initial public offering (IPO) by 50% to 3 million shares. However, they have maintained their share price range of $6 to $8.
Ispire's prospectus for initial public offering
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
